Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217229 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01217229 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 20 participants.
The verdict
NCT01217229, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.The primary objective of this study is to evaluate the efficacy, as measured by overall response rate, of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin lymphoma (HL). Secondary objectives include safety, the duration of response, the disease control rate, progression free survival, and how the drug affects your body.
Interventions
- DRUG PLX3397
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-03-03 |
| Est. Completion | 2012-04-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217229
The ClinicalTrials.gov registry entry for NCT01217229 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX3397 is the first listed.
NCT01217229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01217229 about?
NCT01217229 is a clinical study titled "Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma". PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity.The primary objective of this study is to evaluate the efficacy, as measured by overall response rate, of orally administered PLX3397 in patients with relapsed or refractory classical Hodgkin lymphoma (HL). Secondary objective...
What is the current status of trial NCT01217229?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2011-03-03. Estimated completion is 2012-04-26.
What interventions are being tested in trial NCT01217229?
The interventions under investigation include: PLX3397 (DRUG).
Who is sponsoring clinical trial NCT01217229?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.